Search

everythinglearnresearchcommunity

for

Search:↓

The combination therapy is effective and well-tolerated for treating esophageal cancer.

Ethosomal carriers improve drug delivery through the skin better than traditional methods.

IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.

A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.

Newer retinoid drugs are effective for skin conditions but have significant side effects.

Topical eflornithine helps maintain hair reduction after IPL therapy in women with facial hirsutism.

Erlotinib can cause hair loss and texture changes.

The combination therapy significantly improved Riehl’s melanosis in patients without serious side effects.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

A new microneedle patch effectively treats atopic dermatitis by reducing skin stress and restoring immune balance.

A woman developed a severe skin reaction after getting a birth control implant.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

The combination therapy of PEG-IFN α-2a and Ribavirin can cause widespread hair loss and skin reactions.

TRASER effectively targets blood vessels and hair follicles for potential use in vascular and hair removal treatments.

EGFR inhibitors for lung cancer can cause severe skin issues.

The artificial skin promotes better wound healing and skin regeneration.

Euph E and Euri A from Euphorbia neriifolia help control inflammation and immune response in cells.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Oxymetazoline cream 1.0% effectively reduces rosacea redness, and using baseline photos improves assessment accuracy.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

Quercetin delivery systems are improving its effectiveness for medical use.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.